The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1315
June 29, 2009
View Complete Issue         Table of Contents 2019 
Issue 1315
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: Biennial IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis
June 29, 2009 (Issue: 1315)
The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid (Reclast – Novartis) once a year for treatment of postmenopausal osteoporosis (Med Lett Drugs Ther 2007; 49:89), has now approved the same dose for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1315
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.